AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Osteogenesis Imperfecta

Recent research efforts aimed at curing Osteogenesis Imperfecta.

Last updated

Osteogenesis Imperfecta

Overview

Osteogenesis imperfecta (OI), often called “brittle bone disease,” is a group of inherited connective-tissue disorders in which bones break unusually easily. Most cases are caused by disease-causing variants in COL1A1 or COL1A2, the genes that encode type I collagen, a major structural protein in bone; OI can also affect teeth, hearing, joints, lungs, and other tissues. Severity ranges from relatively mild recurrent fractures with normal stature and life expectancy to severe progressive bone deformity, impaired mobility, respiratory complications, and forms that can be lethal around birth. GeneReviews overview

There is currently no approved treatment that corrects the causal genetic defect throughout the body. Standard care is multidisciplinary and aims to prevent fractures, preserve mobility and independence, and manage complications through physical and occupational therapy, orthopedic surgery such as intramedullary rodding, pain and dental/hearing care, and—particularly in moderate-to-severe disease—bone-resorption drugs called bisphosphonates. GeneReviews management Orphanet clinical summary

Scope of Recent Research (2020–present)

Research activity has accelerated across gene editing, cell therapy, molecular stress reduction, and bone-building biologics. The central challenge is that OI is genetically and clinically diverse: a durable cure must safely reach enough bone-forming cells, correct or neutralize many possible mutations, and address disease beyond bone. As of October 26, 2026, no human gene-therapy or gene-editing treatment has entered clinical testing for OI, so curative therapy remains preclinical; however, animal studies now provide proof-of-concept that directly repairing or bypassing collagen defects can substantially improve skeletal disease. Curative cell and gene therapy review AAV gene-editing study

Major Breakthroughs and Emerging Therapies

In vivo gene editing and gene replacement. The most direct curative strategy is to repair a pathogenic collagen variant in bone-forming cells. In 2024, investigators delivered CRISPR-Cas9 and a repair template using two recombinant adeno-associated virus (AAV) vectors to mice with a severe Col1a2 OI mutation. Systemic treatment improved bone architecture, mineralization, deformity, grip strength, and spontaneous fractures, making this the first reported AAV-delivered homology-directed collagen-gene correction to reverse skeletal features in an OI mouse model. This is an important advance, but it remains an animal result rather than a human therapy. AAV gene editing in OI mice

Patient-specific editing and repaired-cell approaches. Multiple groups have corrected COL1A1 variants in patient-derived induced pluripotent stem cells (iPSCs)—cells reset to an early developmental state and then differentiated into osteoblasts, the cells that make bone. Corrected iPSC-derived osteoblasts produced more normal type I collagen and showed improved bone-forming capacity in laboratory experiments. Separately, gene-modified autologous adipose-derived progenitor cells improved bone microstructure and mechanical properties after local transplantation in a mouse model. These approaches demonstrate biological feasibility, but personalized manufacturing, long-term cell survival, tumor risk, and safe delivery to the skeleton remain unresolved. CRISPR correction in patient iPSCs COL1A1-modified progenitor cells in mice

Targeting cellular stress caused by misfolded collagen. Some collagen mutations cause abnormal collagen to accumulate in the endoplasmic reticulum, a cell compartment that processes proteins. The chemical chaperone 4-phenylbutyrate (4-PBA) reduced this stress in OI models. In mice with a structural Col1a1 mutation, 4-PBA improved growth, cortical bone thickness, bone volume, and fracture incidence; in a different model, it improved linear growth without correcting bone fragility. This suggests that stress-reduction drugs may become genotype-specific add-on treatments rather than universal cures. 4-PBA in an OI mouse model 4-PBA and growth deficiency

Bone-anabolic and pathway-directed medicines. These medicines do not repair the mutated gene, but they may meaningfully reduce disease burden while curative technologies mature. Setrusumab, an antibody that blocks sclerostin—a natural brake on bone formation—improved bone density and measures of estimated bone strength in the Phase 2b ASTEROID trial in adults with OI. ASTEROID Phase 2b results Another emerging agent, AGA2115, is a bispecific antibody designed to block both sclerostin and DKK1, two inhibitors of Wnt signaling, a pathway important for bone formation. In a company-sponsored Phase 1 study in healthy volunteers, it increased bone-formation markers and bone mineral density, supporting an ongoing Phase II OI study. AGA2115 Phase 1 abstract

Clinical Trials and Experimental Approaches

Setrusumab has produced the largest recent late-stage clinical dataset. In the Phase 2b ASTEROID study, monthly intravenous setrusumab increased lumbar-spine and hip bone mineral density over 12 months, although that study was not designed to establish a definitive fracture-prevention effect. ASTEROID Phase 2b results However, on December 29, 2025, sponsor-reported Phase 3 results from the placebo-controlled ORBIT study in participants aged 5–25 years and the active-controlled COSMIC study in children aged 2 to under 7 years did not meet their primary endpoints for reducing annualized clinical fracture rate versus placebo or intravenous bisphosphonates, respectively. Both trials showed statistically significant bone-density improvements, illustrating that higher bone density does not automatically prove fewer fractures in OI. Setrusumab Phase 3 announcement

BOOSTB4/BT-101 is an international Phase I/II study of repeated infusions of donor-derived fetal mesenchymal stromal cells, including prenatal treatment in selected severe cases. The trial is designed primarily around safety and tolerability, with fracture frequency, growth, bone density, donor-cell engraftment, and quality-of-life measures as secondary or exploratory outcomes. BOOSTB4 protocol A 2025 conference report described 18 treated children, 67 postnatal doses, three prenatal doses, no identified short-term product-related serious safety signal, and an approximately 70% reduction in fractures during the 12 months after postnatal treatment compared with pretreatment rates. These findings are encouraging but are preliminary, uncontrolled, and not yet a peer-reviewed efficacy publication. BOOSTB4 conference results BOOST Pharma describes BT-101 as “Phase III-ready,” rather than already in a pivotal trial. BT-101 clinical-development update

The randomized Phase II IDUN trial is evaluating AGA2115 in adults with OI caused by COL1A1 and/or COL1A2 variants, with lumbar-spine bone mineral density at month 12 as its primary objective. European trial records list Angitia as sponsor and an estimated global completion date in 2029. IDUN trial record

Methodologies and Scientific Approaches

Researchers combine genetically precise laboratory models with clinically relevant skeletal measurements. Patient fibroblasts or blood cells are reprogrammed into iPSCs and differentiated into osteoblasts or mesenchymal stromal cells, allowing scientists to compare a patient’s uncorrected cells with otherwise identical gene-corrected cells. These systems are used to test collagen secretion, protein misfolding, mineralization, osteoblast differentiation, and candidate drugs in a genotype-specific manner. Patient-derived iPSC correction study Patient-derived mesenchymal-cell modeling

For whole-body experiments, investigators use mouse models carrying Col1a1 or Col1a2 mutations that reproduce bone fragility, deformity, and fractures. They measure bone density and architecture by micro-computed tomography, bone strength by mechanical testing, fracture frequency, circulating bone-turnover markers, and cell-level outcomes such as osteoblast activity and endoplasmic-reticulum stress. AAV vectors are being engineered to deliver editing tools to osteoblast-lineage cells, while cell-therapy studies track safety, immune effects, donor-cell persistence, and possible paracrine signaling—beneficial factors released by transplanted cells. AAV gene editing in OI mice BOOSTB4 protocol

Leading Institutions and Funding

Important academic and clinical contributors include UMass Chan Medical School’s Horae Gene Therapy Center, which led the recent AAV/CRISPR mouse work; Karolinska Institutet and its European BOOSTB4 partners; Baylor College of Medicine and the Brittle Bone Disorders Consortium; McGill University/Shriners Hospitals; Oregon Health & Science University; and major OI referral centers participating in multicenter trials. AAV gene-editing study TGF-β OI trial BOOSTB4 protocol

Industry programs include BOOST Pharma’s BT-101 cell therapy, Ultragenyx and Mereo’s setrusumab program, and Angitia’s AGA2115 program. Public and nonprofit support remains essential: the Baylor-led anti–TGF-β trial reported support from the NIH-funded Brittle Bone Disorders Consortium (U54AR068069), the National Institute of Child Health and Human Development, the U.S. Department of Agriculture, and Sanofi Genzyme. TGF-β OI trial The Osteogenesis Imperfecta Foundation offers Michael Geisman Fellowships of up to $50,000 per year and, with the Canadian OI Society, Francis Glorieux Fellowships of up to CAD $75,000 per year. OI Foundation research grants

Strengths, Limitations, and Challenges

The strongest recent progress is the transition from broad symptom management toward biologically targeted interventions. AAV-mediated editing has corrected a collagen defect and improved fractures in mice; gene-corrected patient cells recover important osteoblast functions; and cell therapy has advanced into early clinical testing. AAV gene editing in OI mice CRISPR correction in patient iPSCs Yet a mouse skeleton is not a human skeleton, and a therapy that benefits one mutation or one OI subtype may not work for another. Dominant-negative collagen variants are especially difficult because the harmful allele must often be repaired or selectively silenced while preserving enough normal collagen production. Curative cell and gene therapy review

Delivery and durability are major barriers. Systemic gene editing must reach a large, distributed population of bone-forming and skeletal stem cells without unacceptable immune reactions, off-target edits, unwanted DNA integration, or toxicity from high vector doses. Cell therapies may act mainly through short-lived signaling effects rather than permanently replacing defective osteoblasts, and their early clinical evidence is based on small, uncontrolled cohorts. Mesenchymal stem-cell review The setrusumab Phase 3 outcome further shows the importance of patient-centered endpoints: improvements in bone mineral density are valuable but cannot substitute for convincing reductions in fractures, pain, disability, and other lifelong complications. Setrusumab Phase 3 announcement

Outlook and Future Directions

A true cure for OI is not imminent, but the field has moved from theoretical discussion to credible preclinical correction of collagen mutations and increasingly sophisticated early clinical cell-therapy programs. The most important milestones to watch are peer-reviewed, long-term BOOSTB4 results; initiation and outcome of a BT-101 pivotal trial; Phase II results for AGA2115; and replication of AAV gene-editing results in additional OI genotypes, larger animals, and safety studies. The likely path forward is precision medicine: therapies matched to whether an individual has reduced collagen quantity, structurally abnormal collagen, cellular stress, or a non-collagen genetic form of OI. AAV gene-editing study BOOSTB4 protocol IDUN trial record

References

Don't see your disease? Request a report